Cargando…

Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study

OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is one common arrhythmia in the elderly. However, use of antithrombotic therapy in this population is not well known in the People’s Republic of China. This study aimed at investigating antithrombotic therapy status in elderly patients with NVAF in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Wei, Zhang, Jingwei, Liu, Meilin, Liu, Fang, Feng, Xueru, Wang, Yuchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354427/
https://www.ncbi.nlm.nih.gov/pubmed/25767378
http://dx.doi.org/10.2147/CIA.S67974
_version_ 1782360762311770112
author Xiang, Wei
Zhang, Jingwei
Liu, Meilin
Liu, Fang
Feng, Xueru
Wang, Yuchuan
author_facet Xiang, Wei
Zhang, Jingwei
Liu, Meilin
Liu, Fang
Feng, Xueru
Wang, Yuchuan
author_sort Xiang, Wei
collection PubMed
description OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is one common arrhythmia in the elderly. However, use of antithrombotic therapy in this population is not well known in the People’s Republic of China. This study aimed at investigating antithrombotic therapy status in elderly patients with NVAF in our hospital. METHODS: A cross-sectional study of consecutive geriatric patients aged ≥60 years with NVAF who discharged from our hospital between January 2012 and December 2013 were collected. CHA(2)DS(2)-VASc score (cardiac failure or dysfunction, hypertension, age ≥75 [doubled], diabetes, stroke or transient ischemic attack [doubled], vascular disease, age 65–74, and sex category [female]) was used to analyze antithrombotic indication. RESULTS: We consecutively collected data of 1,000 discharged elderly patients (≥60 years) with NVAF (mean age 75.3±8.0 years, 75 years or older 54.7%, female 42.7%). The proportion of paroxysmal atrial fibrillation and non-paroxysmal atrial fibrillation (persistent or permanent) patients were 39.4% and 60.6%, respectively. Among 1,000 patients, 29.1% received oral anticoagulant therapy (OAT), including warfarin (27.8%) and novel oral anticoagulants (1.3%), 39.5% of patients received antiplatelet therapy, and 31.4% received neither therapy. Based on CHA(2)DS(2)-VASc score for stroke risk stratification, 68.9% patients with score ≥1 and 70.2% patients with score ≥2 received antithrombotic therapy, while the rates of OAT were 29.1% and 29.5%, respectively. Among patients with high stroke risk, those with paroxysmal atrial fibrillation were less likely to receive OAT compared with the patients with non-paroxysmal atrial fibrillation (19.5% vs 35.7%, P<0.001). The patients ≥75 years old had lower rate of OAT than the patients <75 years old (25.8% vs 34.8%, P=0.003). The patients with coronary artery disease had lower rate of OAT than the patients without coronary artery disease (24.4% vs 33.4%, P=0.003). Sex and history of stroke or transient ischemic attack had no effect on the use of OAT (30.8% vs 27.9%, P=0.326 and 28.8% vs 29.8%, P=0.761, respectively). CONCLUSION: OAT in elderly patients with NVAF in our hospital is underused, especially in those patients with higher risk of stroke.
format Online
Article
Text
id pubmed-4354427
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43544272015-03-12 Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study Xiang, Wei Zhang, Jingwei Liu, Meilin Liu, Fang Feng, Xueru Wang, Yuchuan Clin Interv Aging Original Research OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is one common arrhythmia in the elderly. However, use of antithrombotic therapy in this population is not well known in the People’s Republic of China. This study aimed at investigating antithrombotic therapy status in elderly patients with NVAF in our hospital. METHODS: A cross-sectional study of consecutive geriatric patients aged ≥60 years with NVAF who discharged from our hospital between January 2012 and December 2013 were collected. CHA(2)DS(2)-VASc score (cardiac failure or dysfunction, hypertension, age ≥75 [doubled], diabetes, stroke or transient ischemic attack [doubled], vascular disease, age 65–74, and sex category [female]) was used to analyze antithrombotic indication. RESULTS: We consecutively collected data of 1,000 discharged elderly patients (≥60 years) with NVAF (mean age 75.3±8.0 years, 75 years or older 54.7%, female 42.7%). The proportion of paroxysmal atrial fibrillation and non-paroxysmal atrial fibrillation (persistent or permanent) patients were 39.4% and 60.6%, respectively. Among 1,000 patients, 29.1% received oral anticoagulant therapy (OAT), including warfarin (27.8%) and novel oral anticoagulants (1.3%), 39.5% of patients received antiplatelet therapy, and 31.4% received neither therapy. Based on CHA(2)DS(2)-VASc score for stroke risk stratification, 68.9% patients with score ≥1 and 70.2% patients with score ≥2 received antithrombotic therapy, while the rates of OAT were 29.1% and 29.5%, respectively. Among patients with high stroke risk, those with paroxysmal atrial fibrillation were less likely to receive OAT compared with the patients with non-paroxysmal atrial fibrillation (19.5% vs 35.7%, P<0.001). The patients ≥75 years old had lower rate of OAT than the patients <75 years old (25.8% vs 34.8%, P=0.003). The patients with coronary artery disease had lower rate of OAT than the patients without coronary artery disease (24.4% vs 33.4%, P=0.003). Sex and history of stroke or transient ischemic attack had no effect on the use of OAT (30.8% vs 27.9%, P=0.326 and 28.8% vs 29.8%, P=0.761, respectively). CONCLUSION: OAT in elderly patients with NVAF in our hospital is underused, especially in those patients with higher risk of stroke. Dove Medical Press 2015-03-02 /pmc/articles/PMC4354427/ /pubmed/25767378 http://dx.doi.org/10.2147/CIA.S67974 Text en © 2015 Xiang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Xiang, Wei
Zhang, Jingwei
Liu, Meilin
Liu, Fang
Feng, Xueru
Wang, Yuchuan
Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
title Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
title_full Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
title_fullStr Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
title_full_unstemmed Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
title_short Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
title_sort antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354427/
https://www.ncbi.nlm.nih.gov/pubmed/25767378
http://dx.doi.org/10.2147/CIA.S67974
work_keys_str_mv AT xiangwei antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy
AT zhangjingwei antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy
AT liumeilin antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy
AT liufang antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy
AT fengxueru antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy
AT wangyuchuan antithrombotictherapyinelderlypatientswithnonvalvularatrialfibrillationapilotstudy